Summary of McKesson's 2025 Conference Call Company Overview - **Company**: McKesson Corporation (NYSE: MCK) - **Event**: UBS Healthcare Conference - **Date**: November 10, 2025 Key Points Industry Insights - **North American Pharmaceutical Business**: McKesson has resegmented its business to provide clarity on strategies, separating specialty oncology from the North American Pharmaceutical segment, which includes the US Pharma and Canadian distribution businesses [3][5][6] - **Market Trends**: The company has observed consistent growth in utilization, driven by demographic trends and innovations in drug development and distribution [7][9] - **Specialty Drugs**: There is a notable shift towards specialty drugs, which are becoming a larger part of the business mix, contributing to improved margins [9][10] Financial Performance - **Operating Expense Leverage**: Over the past five years, McKesson has improved its operating expense leverage by over 1,000 basis points, attributed to investments in automation and technology [17][18] - **Revenue Growth**: The adjusted EPS guidance for the year is between $38.35 and $38.85, representing a growth of 16%-18%, or 18%-20% when excluding prior year gains [63] Strategic Initiatives - **Automation and AI**: McKesson is investing in automation and AI to enhance operational efficiency, with a new distribution center in Ohio being 90% automated [16][18] - **Oncology and Specialty Services**: The company is focused on expanding its oncology services and exploring opportunities in other specialties, particularly in high drug spend areas like retina and ophthalmology [35][44] Pricing and Market Dynamics - **Generic Pricing**: The pricing environment for generics has been stable, with month-to-month variations not significantly impacting long-term strategies [21][22] - **Impact of Legislation**: McKesson does not foresee direct impacts from recent legislative changes regarding drug pricing, as they continue to negotiate fair value for their services [24][25] Future Opportunities - **Clinical Trials and Research**: McKesson sees potential in expanding clinical trial access and management through its Sarah Cannon Research Institute joint venture, which could enhance its oncology platform [33][34] - **New Therapeutic Areas**: The company is exploring opportunities in other therapeutic areas with high innovation and drug spend, beyond oncology and ophthalmology [44][45] Operational Considerations - **Working Capital Management**: McKesson is focused on efficient working capital management, ensuring that fixed fees for services remain unaffected by fluctuations in drug prices [28][29] - **GPO and MSO Dynamics**: The Group Purchasing Organization (GPO) services a wide range of providers, and the company is looking to grow beyond drug distribution into additional service offerings [49] Conclusion - McKesson is strategically positioned to leverage its capabilities in the North American pharmaceutical market, focusing on specialty drugs, operational efficiency through automation, and expanding its oncology services while navigating the evolving regulatory landscape. The company anticipates continued growth and opportunities in high drug spend areas, supported by its investments in technology and clinical services.

Core Insights - McKesson Corporation reported strong adjusted earnings per share (EPS) of $9.86 for Q2 fiscal 2026, exceeding estimates by 10.5% and showing a year-over-year increase of 39.5% driven by operational growth and acquisitions [1] - Total revenues reached $103.15 billion, a 10.1% increase year-over-year, but fell short of estimates by 1.4% [3] - The company raised its fiscal 2026 EPS guidance to $38.35-$38.85, reflecting confidence in demand and growth across its segments [15] Revenue and Earnings Performance - Adjusted EPS of $9.86 beat the Zacks Consensus Estimate of $8.92, with GAAP EPS reported at $8.92 compared to $1.87 in the prior year [1][2] - Revenues of $103.15 billion increased by 10.1% year-over-year, driven by higher prescription volumes and growth in oncology and specialty products [3] - The North American Pharmaceutical segment generated $86.48 billion in revenue, up 8.1% year-over-year, attributed to increased prescription volumes [7] Segment Analysis - The Oncology & Multispecialty segment reported revenues of $12.04 billion, a significant increase of 31.5% year-over-year, with adjusted operating profit rising 71.1% to $397 million [9] - The Prescription Technology Solutions segment saw revenues of $1.38 billion, up 8.8% year-over-year, with adjusted operating profit increasing 19.7% to $261 million [10] - The Medical-Surgical Solutions segment's revenues remained flat at $2.95 billion, with adjusted operating profit up 2.5% to $249 million [11] Financial Metrics - Adjusted gross profit was $3.53 billion, an increase of 8.9% year-over-year, representing 3.4% of net revenues [12] - Adjusted operating income rose 24.9% to $1.57 billion, with an operating margin of 1.5%, expanding nearly 18 basis points year-over-year [13] - Cash and cash equivalents increased to $4 billion from $2.42 billion in the previous quarter, with cumulative net cash from operating activities at $1.5 billion [14] Strategic Initiatives - McKesson is modernizing its distribution through automation and compliance with DSCSA, enhancing its operational capabilities [18] - The company is advancing its portfolio transformation, including plans to spin off the Medical-Surgical Solutions business by the second half of calendar 2027 [18] - New capabilities in high-complexity therapies and rising demand for automated access tools are expected to drive future growth [17]

Core Insights - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] Group 1 - The article suggests that users may face blocks if they have ad-blockers enabled [1]

Core Insights - McKesson reported revenue of $103.15 billion for the quarter ended September 2025, reflecting a year-over-year increase of 10.1% [1] - The earnings per share (EPS) was $9.86, up from $7.07 in the same quarter last year, resulting in an EPS surprise of +10.54% compared to the consensus estimate of $8.92 [1] Revenue Performance - Prescription Technology Solutions revenue was $1.38 billion, slightly below the average estimate of $1.39 billion, with a year-over-year increase of +8.8% [4] - Medical-Surgical Solutions revenue was $2.95 billion, matching a 0% change year-over-year, but below the estimated $3.02 billion [4] - Oncology & Multispecialty revenue reached $12.04 billion, slightly exceeding the estimate of $12.02 billion [4] - Other revenue was reported at $302 million, surpassing the average estimate of $269 million [4] - North American Pharmaceutical revenue was $86.48 billion, below the estimated $88.02 billion [4] Adjusted Operating Profit - Adjusted Operating Profit for Medical-Surgical Solutions was $249 million, slightly above the estimate of $246.33 million [4] - Adjusted Operating Profit for Prescription Technology Solutions was $261 million, exceeding the estimate of $245.96 million [4] - Adjusted Operating Profit for North American Pharmaceutical was $851 million, significantly above the estimate of $772.24 million [4] - Adjusted Operating Profit for Oncology & Multispecialty was $397 million, above the estimate of $356.64 million [4] - Adjusted Operating Profit for Corporate was reported at -$151 million, better than the estimate of -$166.06 million [4] - Adjusted Operating Profit for Other was $25 million, exceeding the estimate of $13.11 million [4] Stock Performance - McKesson shares have returned +12.2% over the past month, outperforming the Zacks S&P 500 composite's +1% change [3] - The stock currently holds a Zacks Rank 1 (Strong Buy), indicating potential for further outperformance in the near term [3]

Core Insights - McKesson reported quarterly earnings of $9.86 per share, exceeding the Zacks Consensus Estimate of $8.92 per share, and up from $7.07 per share a year ago, representing an earnings surprise of +10.54% [1][2] - The company posted revenues of $103.15 billion for the quarter ended September 2025, which missed the Zacks Consensus Estimate by 1.45%, compared to $93.65 billion in the same quarter last year [2] - McKesson's stock has increased approximately 47.7% year-to-date, significantly outperforming the S&P 500's gain of 15.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $9.99, with expected revenues of $105.75 billion, and for the current fiscal year, the EPS estimate is $38.05 on revenues of $409.17 billion [7] - The estimate revisions trend for McKesson was favorable prior to the earnings release, resulting in a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Dental Supplies industry, to which McKesson belongs, is currently ranked in the top 24% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - The performance of McKesson's stock may also be influenced by the overall industry outlook, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Financial Performance - Revenues for Q2 2025 reached $103,150 million, a 10.7% increase from $93,651 million in Q2 2024[9] - Net income attributable to McKesson Corporation for Q2 2025 was $1,110 million, compared to $241 million in Q2 2024, representing a significant increase of 360.6%[9] - Gross profit for the six months ended September 30, 2025, was $6,821 million, up from $6,400 million in the same period last year, reflecting a 6.6% growth[9] - Operating income for Q2 2025 was $1,407 million, a 142.6% increase from $578 million in Q2 2024[9] - Diluted earnings per share for Q2 2025 was $8.92, compared to $1.87 in Q2 2024, marking a 376.5% increase[9] - Comprehensive income for Q2 2025 was $1,100 million, compared to $264 million in Q2 2024, representing a 317.4% increase[11] - For the six months ended September 30, 2025, net income was $1,994 million, compared to $1,247 million for the same period in 2024, representing a 60% increase[20] Assets and Liabilities - Total assets as of September 30, 2025, were $84,160 million, up from $75,140 million as of March 31, 2025, indicating a growth of 12.5%[14] - Current liabilities increased to $68,031 million from $61,604 million, reflecting an increase of 10.4%[14] - Cash and cash equivalents decreased to $4,004 million from $5,691 million, a decline of 29.6%[14] - The company reported a decrease in cash, cash equivalents, and restricted cash of $1,847 million, ending the period with $4,004 million[20] - Total long-term debt increased to $7.76 billion as of September 30, 2025, up from $5.65 billion as of March 31, 2025[94] Dividends and Share Repurchases - The company declared cash dividends of $0.82 per common share for Q2 2025, compared to $0.71 per common share in Q2 2024[16] - Cash dividends declared were $1.53 per common share, totaling $192 million for the period[20] - The Company has authorized a share repurchase plan, with repurchases dependent on various factors including stock price and market conditions[158] - The total number of shares repurchased in Q1 2025 was 0.8 million at an average price of $709.84 per share, and in Q2 2025, 1.2 million shares were repurchased at an average price of $693.25 per share[161] - As of September 30, 2025, the approximate dollar value of shares that may yet be purchased under the repurchase program was $6,070 million[161] Acquisitions and Disposals - The Company acquired an 80% controlling interest in PRISM Vision for $871 million in cash, with a total estimated fair value of consideration at $912 million[35][39] - The Company acquired a 70% controlling interest in Core Ventures for $2.5 billion in cash, with a total estimated fair value of consideration at $3.181 billion[40][44] - The Company completed the sale of its Canadian retail disposal group for a total adjusted purchase price of $129 million, including a cash payment of $9 million and a note of $120 million[46] - The Company recorded net charges of $667 million for the Canadian retail disposal group to remeasure it to fair value less costs to sell[47] - The company entered into a definitive agreement to sell its Norwegian operations during the six months ended September 30, 2025, with the transaction subject to customary closing conditions[184] Segment Performance - The company operates in four reportable segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions[22] - North American Pharmaceutical segment revenue increased to $86,481 million for the three months ended September 30, 2025, up from $80,018 million in the same period of 2024, representing a growth of 5.8%[188] - Oncology & Multispecialty segment revenue rose to $12,044 million for the three months ended September 30, 2025, compared to $9,157 million in 2024, marking a significant increase of 31.0%[188] - Prescription Technology Solutions segment revenue was $1,376 million for the three months ended September 30, 2025, a slight increase from $1,265 million in the same period of 2024, reflecting a growth of 8.8%[188] - Medical-Surgical Solutions segment revenue remained stable at $2,947 million for the three months ended September 30, 2025, compared to $2,946 million in 2024[188] Legal and Regulatory Matters - The Company has paid approximately $2.5 billion as of September 30, 2025, under a settlement agreement with 48 states and will pay up to approximately $5.4 billion through 2038[138] - The estimated total litigation liabilities for opioid-related claims as of September 30, 2025, amount to $5.72 billion, down from $6.38 billion as of March 31, 2025[148] - The Company is vigorously defending itself against various claims and legal proceedings related to the distribution of controlled substances[136] - The Company has recorded a liability for opioid-related claims when a loss is probable and reasonably estimable, reflecting ongoing legal uncertainties[135] - The Company is establishing a clearinghouse to consolidate controlled-substance distribution data as part of its settlement efforts[138] Tax and Compliance - Income tax expense for the three months ended September 30, 2025, was $232 million, with a reported income tax rate of 16.6%, compared to $247 million and 46.3% for the same period in 2024[63][65] - The company recognized a discrete tax benefit of $119 million during the three months ended September 30, 2025, related to the release of a valuation allowance in a foreign jurisdiction[65] - The company had $1.6 billion of unrecognized tax benefits as of September 30, 2025, with $1.4 billion potentially reducing income tax expense if recognized[69] - The company maintains compliance with all covenants under its credit facilities as of September 30, 2025[102] Risk Management - The company is exposed to foreign currency exchange rate risks and utilizes foreign currency forward contracts and cross-currency swaps to mitigate these risks[105] - Interest rate risk is managed through the use of interest rate swaps and forward contracts to hedge fluctuations in benchmark interest rates[106] - The fair value of the company's long-term debt as of September 30, 2025, was $7.831 billion, compared to a carrying value of $7.758 billion[129] Other Comprehensive Income - The accumulated other comprehensive loss as of September 30, 2025, was $908 million, reflecting a decrease from $898 million as of June 30, 2025[166] - For the three months ended September 30, 2025, the company recorded other comprehensive income (loss) of $(10) million, including gains of $98 million related to net investment hedges[167]

Financial Data and Key Metrics Changes - Consolidated revenues increased 10% year over year to $103 billion, with adjusted earnings per diluted share rising 39% to $9.86 [5][20][41] - Operating profit reached a record $1.6 billion, up 26% year over year, driven by growth across all operating segments [23][41] - Gross profit increased 9% to $3.5 billion, primarily due to strong specialty distribution and provider growth [22] Business Line Data and Key Metrics Changes - North American pharmaceuticals segment revenues were $86.5 billion, an increase of 8%, with operating profit rising 13% to $851 million [25][41] - Oncology and multi-specialty segment revenues increased 32% to $12 billion, with operating profit up 71% to $397 million, driven by strong provider and specialty distribution growth [27][41] - Prescription technology solutions segment revenues rose 9% to $1.4 billion, with operating profit increasing 20% to $261 million [28][41] - Medical-surgical solutions segment revenues were flat at $2.9 billion, with operating profit increasing 2% to $249 million [29][41] Market Data and Key Metrics Changes - Revenues from GLP-1 medications were $13.2 billion, a 24% increase year over year [26] - The oncology business continues to see good traffic and volumes, benefiting from new partners and complicated oncology-type patients [65] Company Strategy and Development Direction - The company introduced a new reporting structure to enhance transparency and sharpen visibility into growth platforms, focusing on oncology and multi-specialty, and biopharma services [21][34] - The strategy includes significant investments in automation and technology to improve operational efficiency and customer experience [14][15][41] - The company is targeting to exit the medical-surgical solutions business through an initial public offering by the second half of calendar 2027 [17][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business outlook, raising guidance for adjusted earnings per diluted share to a range of $38.35-$38.85, reflecting strong second-quarter performance [5][34] - The company anticipates revenue growth of 11%-15% and operating profit growth of 12%-16% for fiscal 2026 [35][41] - Management highlighted the importance of maintaining discipline in reviewing the portfolio and market decisions [66][67] Other Important Information - The company ended the quarter with $4 billion in cash and cash equivalents, indicating strong liquidity [30] - Free cash flow for the second quarter was $2.2 billion, reflecting disciplined working capital management [30] Q&A Session Summary Question: Understanding revenue growth versus operating profit expansion - Management noted that operating margin expansion was seen across all segments, driven by new products and enhanced programs [44][45] Question: Oncology and multi-specialty segment guidance - Management indicated that strong growth was driven by acquisitions, with organic growth at about 13% year over year [53] Question: Health system business performance - Management expressed satisfaction with the health system business, noting strong volumes and market-leading share [57] Question: Tax rate guidance for the year - Management clarified that the tax rate could vary, with an anticipated range of 18%-19% for the full year [60][61] Question: Impact of cash pay channel on prior authorization business - Management stated that the impact of cash pay channels is expected to be minimal, as the eligible population remains small [76][78] Question: SG&A and gross profit trends - Management attributed the trends to a favorable mix of businesses and continued focus on efficiency [83][84]

Financial Data and Key Metrics Changes - Consolidated revenues increased 10% year-over-year to $103 billion, with adjusted earnings per diluted share rising 39% to $9.86 [5][21][39] - Gross profit increased 9% to $3.5 billion, while operating profit reached a record of $1.6 billion, up 26% year-over-year [22][23] - Interest expense declined 6% to $68 million, and the effective tax rate was 17.5%, down from 21% in the prior year [24][39] Business Line Data and Key Metrics Changes - North American Pharmaceuticals segment revenues were $86.5 billion, an increase of 8%, with operating profit up 13% to $851 million [25][26] - Oncology and Multispecialty segment revenues increased 32% to $12 billion, with operating profit rising 71% to $397 million [26][27] - Prescription Technology Solutions segment revenues increased 9% to $1.4 billion, with operating profit up 20% to $261 million [27] Market Data and Key Metrics Changes - Revenues from GLP-1 medications were $13.2 billion, a 24% increase year-over-year [26] - The company reported strong performance in health systems, benefiting from increased traffic and market-leading share [55] Company Strategy and Development Direction - The company introduced a new reporting structure to enhance transparency and focus on growth areas, specifically in Oncology and Multispecialty segments [6][21] - The strategy includes significant investments in automation and technology to improve operational efficiency and customer experience [14][15][39] - The company is targeting to separate the Medical-Surgical Solutions business through an IPO, expected to be completed by the second half of calendar 2027 [17][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business outlook, raising guidance for adjusted earnings per diluted share to $38.35-$38.85, reflecting strong first-half performance [5][33] - The company anticipates revenue growth of 11%-15% and operating profit growth of 12%-16% for fiscal 2026 [34][39] Other Important Information - The company reported a free cash flow of $2.2 billion for the quarter, with $4 billion in cash and cash equivalents [29][39] - Corporate expenses were flat year-over-year at $151 million, reflecting operational efficiencies [28][39] Q&A Session Summary Question: Understanding revenue growth versus operating profit expansion - Management noted that operating margin expansion was driven by a mix of new products and enhanced programs, particularly in Prescription Technology Solutions [41][42][43] Question: Oncology and Multispecialty guidance maintenance - Management indicated that strong growth was anticipated, with half driven by acquisitions and organic growth at about 13% year-over-year [49][50][51] Question: Health system strength - Management highlighted strong performance in the health system segment, attributing it to market-leading share and increased volumes [54][55] Question: Tax rate guidance - Management clarified that the tax rate for the second half is expected to be slightly higher, with specific guidance for the third quarter at 23%-25% [58][59] Question: Specialty trend continuation - Management confirmed continued good traffic and volumes in oncology, with a focus on treating more complicated patients [62][63] Question: Cash pay channel impact - Management expressed that the impact of cash pay channels on the prior authorization business is expected to be minimal, emphasizing their commitment to work with policymakers [72][75][76]

Financial Data and Key Metrics Changes - Consolidated revenues increased 10% year over year to $103 billion, with adjusted earnings per diluted share rising 39% to $9.86 [4][18][23] - Operating profit reached a record $1.6 billion, up 26% year-over-year, driven by growth across all operating segments [21][38] - Interest expense declined 6% to $68 million, and the effective tax rate was 17.5%, down from 21% in the prior year [22][23] Business Line Data and Key Metrics Changes - North American pharmaceuticals segment revenues were $86.5 billion, an increase of 8%, with operating profit increasing 13% to $851 million [23][24] - Oncology and multi-specialty segment revenues rose 32% to $12 billion, with operating profit increasing 71% to $397 million [24][25] - Prescription technology solutions segment revenues increased 9% to $1.4 billion, with operating profit rising 20% to $261 million [25] Market Data and Key Metrics Changes - Revenues from GLP-1 medications were $13.2 billion, a 24% increase year-over-year [24] - The oncology and multi-specialty segment's growth was supported by expanded distribution and contributions from recent acquisitions [19][24] Company Strategy and Development Direction - The company introduced a new reporting structure to enhance transparency and sharpen strategic alignment, focusing on oncology and multi-specialty segments [5][18] - The strategy includes significant investments in automation and technology to improve operational efficiency and customer experience [13][14][38] - The company is targeting to separate the medical-surgical solutions business through an initial public offering, expected to be completed by the second half of calendar 2027 [15][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business outlook, raising the guidance for adjusted earnings per diluted share to $38.35-$38.85, reflecting strong second-quarter performance [4][31] - The company anticipates revenue growth of 11%-15% and operating profit growth of 12%-16% for fiscal 2026 [32][38] - Management highlighted the importance of maintaining operational discipline and strategic focus to drive long-term value creation [18][29] Other Important Information - The company ended the quarter with $4 billion in cash and cash equivalents, indicating strong liquidity [28] - Free cash flow for the second quarter was $2.2 billion, with $907 million returned to shareholders through share repurchases and dividends [28][38] Q&A Session Summary Question: Understanding revenue growth versus operating profit expansion - Management noted that operating margin expansion was seen across all segments, driven by a mix of new products and access programs [40][41] Question: Oncology and multi-specialty segment guidance - Management indicated that strong growth was anticipated, with half driven by acquisitions and organic growth at about 13% year-over-year [44][45] Question: Health system business performance - Management expressed satisfaction with the health system business, noting strong volume growth and market-leading share [46] Question: Tax rate guidance for the year - Management clarified that the tax rate for the second half is expected to be slightly higher, with specific guidance for the third quarter at 23%-25% [48] Question: Specialty trend expectations - Management confirmed continued good traffic and volumes in oncology, supported by new partners and complex therapies [49][50] Question: Impact of cash pay channel on prior authorization business - Management stated that the cash pay channel's impact is expected to be minimal, as the eligible population remains small [53][55] Question: SG&A and gross profit trends - Management highlighted the favorable mix of businesses and continued focus on efficiency as key drivers of the observed trends [56][58] Question: Market decisions and gains - Management clarified that the gains from market decisions were non-recurring and included in the reported figures [59][62] Question: Drug Supply Chain Security Act impact - Management noted that the implementation was smooth and added value to services, but it is not expected to be a material driver of growth [63]

Core Insights - McKesson raised its fiscal 2026 profit forecast, indicating confidence in its growth prospects [1] Company Summary - The company is focusing on strong growth in its oncology and specialty drug distribution businesses, which are expected to drive profitability [1]